### Summary ConclusionThis quarter's results met expectations, primarily driven by year-over-year volume and mix improvements across all three business segments, with Nordion particularly benefiting from shipment timing adjustments to post strong growth.

### Key DataTotal revenue grew 8.5% year-over-year, Nordion revenue increased 28%, and adjusted EPS was $0.17, up $0.01 year-over-year.

### Business ProgressSterigenics completed an expansion at one facility and entered customer validation, with NESHAP regulatory retrofits progressing on schedule. Nordion completed its first cobalt insertion at the Darlington reactor, with first harvest expected in 2028, ensuring long-term supply. Nelson Labs saw improved test volumes in its core lab, while expert advisory services revenue continued to normalize.

### GuidanceThe report reaffirms full-year revenue and adjusted EBITDA growth of 4%-6%, but expects Nelson Q4 revenue to decline mid-single digits year-over-year as the high base for expert advisory fades.

### Risks/HighlightsPositive signal: Management expressed strong confidence in NESHAP regulation enforcement, which it believes will benefit the industry. Negative signal: Expert advisory services revenue trends are declining, compounded by expected weakness in Nelson Q4.